Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$82,370.00-1.72%ETH$2,535.82-1.79%GOLD$4,140.900.00%OIL$92.71+5.02%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACXP

Acurx Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.30

Down-$0.01 (-0.76%)

Updated Oct 8, 2026, 10:00 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.38M
P/E ratio
-0.27
Dividend yield
0.00%
52-week range
$1.23 – $7.54
Volume
78.04K
Avg. volume
61.79K

Price performance · ACXP

ACXP price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

ACXP closed at $1.30 after 21 trading sessions, down 7.80% for the selected period.

Last close
$1.30
Period change
-7.80%
Period low
$1.26
Period high
$1.41
Daily close
View OHLC price history
ACXP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$1.32$1.3299$1.28$1.3078.04K
Oct 6, 2026$1.30$1.33$1.28$1.3142.2K
Oct 5, 2026$1.25$1.36$1.25$1.31110.87K
Oct 2, 2026$1.28$1.28$1.245$1.2782.49K
Oct 1, 2026$1.27$1.295$1.25$1.2664.94K
Sep 30, 2026$1.32$1.32$1.23$1.26130.52K
Sep 29, 2026$1.38$1.38$1.27$1.305162.12K
Sep 28, 2026$1.36$1.36$1.33$1.3452.79K
Sep 25, 2026$1.38$1.38$1.35$1.36134.02K
Sep 24, 2026$1.39$1.39$1.345$1.3648.07K
Sep 23, 2026$1.36$1.3849$1.35$1.3758.7K
Sep 22, 2026$1.34$1.3906$1.305$1.36156.19K
Sep 21, 2026$1.39$1.4098$1.31$1.33280.64K
Sep 18, 2026$1.36$1.4193$1.36$1.3957.4K
Sep 17, 2026$1.3856$1.41$1.38$1.3970.43K
Sep 16, 2026$1.37$1.39$1.36$1.3861.27K
Sep 15, 2026$1.39$1.40$1.35$1.35582.11K
Sep 14, 2026$1.40$1.42$1.38$1.3984.35K
Sep 11, 2026$1.41$1.41$1.38$1.4064.71K
Sep 10, 2026$1.41$1.425$1.38$1.4058.78K
Sep 9, 2026$1.4127$1.43$1.41$1.4132.57K

Latest ACXP news

The latest Smart Investors Daily articles mentioning ACXP.

Stock researchCompany · Overview

ACXP research

Overview

Company profile and research snapshot.

Company profile

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ACXP recent ratings
DateFirmRatingTarget
Sep 29, 2026HC Wainwright & Co.Buy—
Sep 30, 2025HC Wainwright & Co.Buy—
Aug 12, 2025HC Wainwright & Co.Buy—
Mar 19, 2025HC Wainwright & Co.Buy—
Jan 13, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the first patient has been enrolled in its new clinical trial (PATHFINDER) in patients with multiply recurrent C. difficile Infection (rCDI). This new, fully funded,PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episo

Yahoo · Sep 19, 2026

New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global

BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By